Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Sihuan Pharmaceutical Holdings Group Debt-to-EBITDA?
Sihuan Pharmaceutical Holdings GroupSHPHF 52 Debt-to-EBITDA is 1.07 as of Dec. 2025, which is 168% above its 10-year median of 0.40. GuruFocus rates SHPHF with a GF Scoreâ„¢ of 52/100 and a GF Valueâ„¢ of $0.16 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 689 Drug Manufacturers companies, Sihuan Pharmaceutical Holdings Group ranks better than 57.91% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SHPHF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.84 Med: 0.4 Max: 9.27
Current: 1.2
During the past 13 years, the highest Debt-to-EBITDA Ratio of Sihuan Pharmaceutical Holdings Group was 9.27. The lowest was -0.84. And the median was 0.40.
SHPHF's Debt-to-EBITDA is ranked better than 57.91% of 689
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs SHPHF: 1.20
Sihuan Pharmaceutical Holdings Group (OTCPK:SHPHF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sihuan Pharmaceutical Holdings Group Debt-to-EBITDA Related Terms
Sihuan Pharmaceutical Holdings Group Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group Debt-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sihuan Pharmaceutical Holdings Group Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Sihuan Pharmaceutical Holdings Group (SHPHF) has a Debt-to-EBITDA of 1.07 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sihuan Pharmaceutical Holdings Group. This is 168% above median its historical median of 0.40. According to the industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #290 out of 689 companies in the Drug Manufacturers industry, placing it in the top 42.1%.
Is Sihuan Pharmaceutical Holdings Group's Debt-to-EBITDA too high?
Sihuan Pharmaceutical Holdings Group's current Debt-to-EBITDA of 1.07 is 168% above median its 10-year median of 0.40. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Sihuan Pharmaceutical Holdings Group's value of 1.07 is 36.3% below this industry median. Based on the distribution chart, Sihuan Pharmaceutical Holdings Group ranks #290 out of 689 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sihuan Pharmaceutical Holdings Group has a GF Scoreâ„¢ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #290 out of 689 companies for Debt-to-EBITDA. This puts Sihuan Pharmaceutical Holdings Group in the upper half of its industry. The industry median Debt-to-EBITDA is 1.68. Sihuan Pharmaceutical Holdings Group's value of 1.07 is 36.3% below this benchmark. While the company's 10-year median is 0.40 vs. the industry median of 1.68, Sihuan Pharmaceutical Holdings Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sihuan Pharmaceutical Holdings Group's current Debt-to-EBITDA of 1.07 is 36.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sihuan Pharmaceutical Holdings Group. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sihuan Pharmaceutical Holdings Group's current Debt-to-EBITDA is 1.07, which is 168% above median its own 10-year median of 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (SHPHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.16, compared to a current price of $0.12 — trading 25% below its estimated fair value. The current Debt-to-EBITDA is 1.07, which is 168% above median its 10-year median of 0.40 and 36.3% below the Drug Manufacturers industry median of 1.68. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (SHPHF), the current Debt-to-EBITDA is 1.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sihuan Pharmaceutical Holdings Group (SHPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued.
The current stock price of $0.12 is trading 25% below its estimated GF Value™ of $0.16.
GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.
Key valuation signals for SHPHF:
Debt-to-EBITDA: 1.07 (168% above median its 10-year median of 0.40)
GF Value™: $0.16 vs. price of $0.12 (25% below fair value)
Industry Position: 36.3% below the Drug Manufacturers median (#290 of 689)
No single metric tells the full story. See the SHPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sihuan Pharmaceutical Holdings Group Business Description
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
52GF Score
Get the complete analysis for SHPHF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPHF has been successfully added to your 
